

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On May 30, 2007

TOWNSEND and TOWNSEND and CREW LLP

By: Brenda J. Dolly

Brenda J. Dolly

PATENT
Attorney Docket No.: 080404-000000US
Client Reference No.: 12627 / KC/nc



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Julian Alexander Barden et al.

Application No.: 10/622,313

Filed: July 17, 2003

For: ANTIBODIES TO NON-
FUNCTIONAL P2X7 RECEPTOR
DIAGNOSIS AND TREATMENT OF
CANCERS AND OTHER CONDITIONS

Examiner: Jon McClelland Lockard

Art Unit: 1645

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR §1.97 and §1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A are being called to the attention of the Examiner. Copies of the references, in compliance with the requirements of 37 CFR §1.98(a)(2), are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no


06/01/2007 WABDELRI 00000028 201430 10622313
01 FC:1806 180.00 DA

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Jennifer L. Wahlsten
Reg. No. 46,226

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
JLW:mtd



<p>Substitute for form 1419 & B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use as many sheets as necessary)</p>				Complete if Known	
				Application Number	10/622,313
				Filing Date	July 17, 2003
				First Named Inventor	BARDEN, Julian Alexander
				Art Unit	1645
				Examiner Name	Jon McClelland Lockard
Sheet	1	of	1	Attorney Docket Number	080404-000000US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AA	BUELL et al., "Blockade of human P2X ₇ receptor function with a monoclonal antibody," <u>Blood</u> , 92(10):3521-3528 (1998).	<input type="checkbox"/>	
	AB	FERRARI et al., "ATP-mediated cytotoxicity in microglial cells," <u>Neuropharmacology</u> , 36(9):1295-1301 (1997).	<input type="checkbox"/>	
	AC	GROSCHERL-STEWART et al., "Localisation of P2X ₅ and P2X ₇ receptors by immunohistochemistry in rat stratified squamous epithelia," <u>Cell Tissue Research</u> , 296(3):599-605 (1999).	<input type="checkbox"/>	
	AD	GU et al., "A Glu-496 to ala Polymorphism leads to loss of function of the human P2X ₇ receptor," <u>J. Biol. Chem.</u> , 276:11135-11142 (2001).	<input type="checkbox"/>	
	AE	CHESSELL et al., "Dynamics of P2X ₇ receptor pore dilation: pharmacological and functional consequences," <u>Drug Dev. Res.</u> , 53(2/3):60-65 (2001).	<input type="checkbox"/>	
	AF	PENG et al., "P2Z purinoceptor, a special receptor for apoptosis induced by ATP in human leukemic lymphocytes," <u>Chinese Medical Journal</u> , 112(4):356-362 (1999).	<input type="checkbox"/>	
	AG	Di VIRGILIO et al., "Purinergic P2X ₇ receptor: a pivotal role in inflammation and immunomodulation," <u>Drug Dev. Res.</u> , 45(3/4):207-213 (1998).	<input type="checkbox"/>	
	AH	WILEY et al., "Genetic polymorphisms of the human P2X ₇ receptor and relationship to function," <u>Drug. Dev. Res.</u> , 53(2/3):72-76 (2001).	<input type="checkbox"/>	
	AI	WILEY et al., "A single nucleotide polymorphism is associated with loss of function of the monocyte P2X ₇ receptor," <u>Blood</u> , 96(11 pt 1):abstract 17a (2000).	<input type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.